DYRK1A and cancer: Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A), proviral insertion site in Moloney murine leukemia virus (PIM), and Haspin (haploid germ cell-specific nuclear protein kinase) have emerged as significant kinase targets for the treatment of cancer, neurodegenerative diseases, and inflammatory diseases at the clinical and preclinical levels [1,2,3,4,5,6].